OBJECTIVE: Although the use of HIV-1 protease inhibitors (PI) has substantially benefited HIV-1-infected individuals, new PI are urgently needed, as broad PI resistance and therapy failure is common. METHODS: The antiviral activity of tipranavir (TPV), a non-peptidic PI, was assessed in in vitro culture for 134 clinical isolates with a wide range of resistance to currently available peptidomimetic PI. The susceptibility of all 134 variants was then re-tested with the four PI simultaneously with TPV, using the Antivirogram assay. RESULTS: Of 105 viruses with more than tenfold resistance to three or four PI and an average of 6.1 PI mutations per sample, 95 (90%) were susceptible to TPV; eight (8%) had four- to tenfold resistance to TPV and only two (2%) had more than tenfold resistance. CONCLUSIONS: The substantial lack of PI cross-resistance to TPV shown by highly PI-resistant clinical isolates makes TPV an attractive new-generation HIV inhibitor.
OBJECTIVE: Although the use of HIV-1 protease inhibitors (PI) has substantially benefited HIV-1-infected individuals, new PI are urgently needed, as broad PI resistance and therapy failure is common. METHODS: The antiviral activity of tipranavir (TPV), a non-peptidic PI, was assessed in in vitro culture for 134 clinical isolates with a wide range of resistance to currently available peptidomimetic PI. The susceptibility of all 134 variants was then re-tested with the four PI simultaneously with TPV, using the Antivirogram assay. RESULTS: Of 105 viruses with more than tenfold resistance to three or four PI and an average of 6.1 PI mutations per sample, 95 (90%) were susceptible to TPV; eight (8%) had four- to tenfold resistance to TPV and only two (2%) had more than tenfold resistance. CONCLUSIONS: The substantial lack of PI cross-resistance to TPV shown by highly PI-resistant clinical isolates makes TPV an attractive new-generation HIV inhibitor.
Authors: Michael D Altman; Akbar Ali; G S Kiran Kumar Reddy; Madhavi N L Nalam; Saima Ghafoor Anjum; Hong Cao; Sripriya Chellappan; Visvaldas Kairys; Miguel X Fernandes; Michael K Gilson; Celia A Schiffer; Tariq M Rana; Bruce Tidor Journal: J Am Chem Soc Date: 2008-04-16 Impact factor: 15.419
Authors: Geoffrey Mukwaya; Thomas MacGregor; David Hoelscher; Thomas Heming; Daniel Legg; Kelli Kavanaugh; Phillip Johnson; John P Sabo; Scott McCallister Journal: Antimicrob Agents Chemother Date: 2005-12 Impact factor: 5.191
Authors: Christopher L Peatey; Katherine T Andrews; Nina Eickel; Timothy MacDonald; Alice S Butterworth; Katharine R Trenholme; Donald L Gardiner; James S McCarthy; Tina S Skinner-Adams Journal: Antimicrob Agents Chemother Date: 2009-12-22 Impact factor: 5.191
Authors: Linzhi Chen; John P Sabo; Elsy Philip; Yanping Mao; Stephen H Norris; Thomas R MacGregor; Jan M Wruck; Sandra Garfinkel; Mark Castles; Amy Brinkman; Hernan Valdez Journal: Antimicrob Agents Chemother Date: 2007-05-07 Impact factor: 5.191
Authors: Anne-Genevieve Marcelin; Bernard Masquelier; Diane Descamps; Jacques Izopet; Charlotte Charpentier; Chakib Alloui; Magali Bouvier-Alias; Anne Signori-Schmuck; Brigitte Montes; Marie-Laure Chaix; Corinne Amiel; Georges Dos Santos; Annick Ruffault; Francis Barin; Gilles Peytavin; Marc Lavignon; Philippe Flandre; Vincent Calvez Journal: Antimicrob Agents Chemother Date: 2008-07-14 Impact factor: 5.191